Device evaluation summary: biocompatibility testing to iso 10993 was successfully completed on skin-contacting surfaces of the lifevest device as well as the blue(tm) defibrillation gel.Belt sn (b)(4) was returned and evaluated at the distributor in accordance with procedures recommended by zoll manufacturing corporation.The evaluation included review of downloaded software flag files and incoming functional testing and passed incoming functional testing.During the incoming functional testing, a 1hz simulated normal sinus rhythm signal was applied to the ecg electrodes, followed by a 5hz simulated treatable arrhythmia signal which verified proper performance of the detection algorithm.During the transition to the 5hz signal, the device was confirmed to properly enter into a treatment sequence which includes a verification of the tactile vibration alarm as well as a test of the pulse delivery circuitry.The pulse delivery circuitry test verified proper delivery of a full energy 150j biphasic pulse.The functional testing confirmed proper ecg acquisition, detection algorithm performance, and pulse delivery functionality.The belt evaluation confirmed that the front therapy electrode was leaking gel.The root cause of the gel leak was unable to be positively identified.
|
A us distributor reported that the patient had developed a skin irritation from the lifevest.The patient had a red rash under the front therapy pad.It was reported that the patient's doctor recommended benadryl cream and that the rash had improved slightly.During a subsequent call, the patient's grandmother reported that the rash had returned and that there was gel leaking from the front therapy pad.They applied hydrocortisone cream and benadryl to the area.During a final follow up, the grandmother reported that the irritation had improved through the use of the benadryl cream.
|